@grandslam... It's discussed in some detail under "Risks Related to Ownership of our Common Stock", and also in a prior 8K. The more I think about it, the more I think it's a bad idea to relist on a major exchange, until and unless they generate some buzz with the clinical trials. If there is no demand for the stock, the price will plummet, even with the tiny float. There must be buyers. And if the price plummets, another delisting will occur, helping no one. If they are only doing this to appease shareholders who want some liquidity, but refuse to do the things necessary to create awareness of their business, it seems to me that a lower key listing on an OTC board would be more appropriate.
News 
Market Data 
Discover 
AI
